|Videos|December 4, 2017

NFID Medical Director Addresses Common Misconceptions Regarding the Flu Vaccine

William Schaffner, MD, addresses common misconceptions regarding the influenza vaccine.

William Schaffner, MD, medical director of the National Foundation for Infectious Diseases, addresses common misconceptions regarding the influenza vaccine.

Interview Transcript (modified slightly for readability):

“I hesitate to mention the misconceptions but I’m afraid that there’s still that myth out there that you can get flu from the flu vaccine. That’s a myth; there’s no truth to it. It may well be that somebody got vaccinated on Monday and on Wednesday they got a cold, and what they’ll do is attribute that cold to having received the vaccine, but there’s no connection. As we all know, the influenza is a killed influenza vaccine, it’s broken up into little pieces, reformulated in the vaccine, it can’t put itself back together again and make an infectious virus. So, you can’t get flu from the flu vaccine.

Now, the other unhappy concept about the flu vaccine is that it doesn’t work well enough. We all wished it would work better, but it’s a pretty darn good vaccine and it’s the best vaccine we have right now. It always prevents many, many infections. And remember, if it doesn’t prevent the infection completely, it will modify the infection; it will make it milder, makes it less likely if you get flu that you have to go to the hospital, be admitted to the intensive care unit, or die.

Nothing that we do in medicine is less expensive, easier to get, and more efficient in providing all that prevention. So, we really ought to insist that our patients get vaccinated, and, of course, we as health care providers absolutely should all be vaccinated, so we don’t give flu to our patients.”


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.